Please ensure Javascript is enabled for purposes of website accessibility

1 Big Pharma That's Not Waving the White Flag

By Dave Williamson – Updated Apr 7, 2017 at 12:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sanofi's (SNY -2.23%)Gaucher disease drug eliglutistat crushed its phase 3 trial, resoundingly beating a placebo and hitting all secondary endpoints as well. Sanofi is the king of Gaucher disease treatment, as its drug cerezyme is the current standard of care for this disease affecting about 6,000 people in the United States. However, cerezyme has to be infused, as does its new and cheaper competitor from Pfizer (PFE)and Protalix BioTherapeutics(PLX). Will a 25% discount make up for the fact that Sanofi's new drug is taken orally instead of injected? That's the company's hope, as it's counting on ease of use to stay one step ahead of the competition.

Check out the video for the full story on Sanofi's promising new treatment option. Remember, though, that while you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Dave Williamson, Max Macaluso, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
Sanofi
SNY
$38.93 (-2.23%) $0.89
Pfizer Stock Quote
Pfizer
PFE
Protalix BioTherapeutics Stock Quote
Protalix BioTherapeutics
PLX

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.